The estimated Net Worth of Elaine Castellanos is at least $12 Milione dollars as of 7 June 2021. Elaine Castellanos owns over 10,000 units of Reata Pharmaceuticals Inc stock worth over $2,507,149 and over the last 8 years Elaine sold RETA stock worth over $9,513,848.
Elaine has made over 16 trades of the Reata Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Elaine sold 10,000 units of RETA stock worth $1,426,500 on 7 June 2021.
The largest trade Elaine's ever made was selling 14,000 units of Reata Pharmaceuticals Inc stock on 15 October 2019 worth over $2,066,260. On average, Elaine trades about 2,645 units every 39 days since 2016. As of 7 June 2021 Elaine still owns at least 14,546 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Elaine Castellanos stock trades at the bottom of the page.
Elaine's mailing address filed with the SEC is 5320 LEGACY DRIVE, , PLANO, TX, 75024.
Over the last 9 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy e Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include: